Patent ID: 11865082
Assignee: HOFFMANN-LA ROCHE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A therapeutic method of treating cancer comprising administering to a subject a combination therapy comprising (a) a programmed death 1 polypeptide (PD-1)-targeted interleukin 2 (IL-2) variant immunocytokine in combination with (b) an antibody which binds to human programmed death ligand 1 (PD-L1),
wherein the PD-1-targeted IL-2 variant immunocytokine comprises:
i) a heavy chain variable domain VH of SEQ ID NO: 5 and a light chain variable domain VL of SEQ ID NO: 6, and the polypeptide sequence of SEQ ID NO: 2, or
ii) the polypeptide sequences of SEQ ID NO: 7, and SEQ ID NO: 8 and SEQ ID NO: 9, or
iii) the polypeptide sequences of SEQ ID NO: 12, and SEQ ID NO: 13 and SEQ ID NO: 14, and wherein the antibody which binds to human PD-L1 comprises

a heavy chain variable domain VH of SEQ ID NO: 19 and a light chain variable domain VL of SEQ ID NO: 20.